Major players in the agricultural biologicals market are Syngenta AG, The Dow Chemical Company, Bayer AG, BASF SE, Isagro Company, Marrone Bio Innovations...

British data highlight factors affecting drug longevity

But hint of benefit suggests the approach might not be a dead end

The 2023 recommendations cover new treatment strategies with more ambitious goals, new data on adverse effects of chronic glucocorticoid use, and newly approved agents and combination therapies.

Peter Lio, MD, says he can't wait to have more flexibility for his pediatric patients

Ustekinumab, adalimumab both effective in SEAVUE trial, with no difference in remissions

The $10 billion Tokyo-based acquirer makes mainly nutritional additives and foods, but sees Grove City's Forge as a launchpad for expanding its healthcare arm into advanced medicine.

Systemic therapy is warranted in patients with moderate-to-severe involvement of specific sites or in those refractory to topical therapy, according to Dr April Armstrong.

E2E enterprise biopharma workflow platform increases R&D efficiency and shortens timelines of discovery projects at world-leading contract research organization

Markedly more effective than conventional DMARDs as first-line therapy

In a systematic review, outcomes such as remission and loss of response were similar between patients with IBD who continued their original biologic and those who switched to a biosimilar.

Year-long freedom from exacerbations without steroids reported in real-world study

Patients with moderate to severe atopic dermatitis could soon have more therapeutic options, with monoclonal antibodies targeting novel immune pathways that reduce disease severity, suggest two trials.

Nearly all required prior authorization in a small study, and requests often rejected at first

A recent approval and more products in the pipeline offer new treatment options.

Although the study was retrospective, it suggests that the threshold for initiating biologics could potentially be lowered for patients with uncontrolled asthma despite adequate use of inhalers.

A Japanese study suggests that biologics and 5-aminosalicylic acid are potentially associated with a lower risk of advanced cancer in patients with ulcerative colitis.

Meta-analysis finds differences between biologics for severe asthma so minimal as to not meet clinically important thresholds.

One might have hoped that these agents would help patients stay on the job

Dr David Rosmarin reviewed several biologics in clinical trials that target interleukin-4 and other receptors.